GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
Pharmacokinetic Study to Evaluate Anti-mycobacterial Activity of TMC207 in Combination With Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) Medications for Treatment of Children/Adolescents With Pulmonary MDR-TB
NCT02354014 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect80/100
StatusSUSPENDED
PhasePHASE2
Lead sponsorJanssen Research & Development, LLC
Last update2026-09-17
Public-record facts
| Intervention | Bedaquiline (TMC207) (DRUG), Background Regimen (BR) (DRUG) |
|---|---|
| Condition | Tuberculosis, Multidrug-Resistant |
| Enrollment | 60 |
| Why stopped | As part of the protocol-specified interim pharmacokinetic (PK) evaluation in Study TMC207-C211, PK data demonstrated lower-than-anticipated bedaquiline exposure |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is suspended and was updated 2026-09-17.
- It is an interventional PHASE2 study with a named drug/drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT02354014. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.